Until clinical staging improves, patients presenting with clinical stage A nonseminomatous testis cancer should be offered the option of initial nerve-sparing RPLND versus surveillance. Either method of management may be successful in the individual patient. We feel each patient with clinical stage A disease must be informed of alternative methods of management and be allowed to choose the method of management that he feels best suits his needs in terms of risk benefit.
|Original language||English (US)|
|Number of pages||5|
|Journal||Seminars in oncology|
|State||Published - Apr 1992|
ASJC Scopus subject areas